Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 27 systematic review(s)/meta-analysis(es). ^[1-28]
• Sotagliflozin significantly reduced hospitalizations for heart failure (HF) and cardiovascular (CV) death compared to empagliflozin (relative risk (RR) = 0.88, 95% confidence interval (CI), 0.79 to 0.97) and dapagliflozin (RR = 0.86, 95% CI, 0.77 to 0.96), demonstrating greater effectiveness in improving HF outcomes.
• In patients with chronic kidney disease, sotagliflozin demonstrated notable reductions in cardiovascular-related deaths and hospitalizations for HF, irrespective of the presence of albuminuria.
• Sotagliflozin also significantly lowered the risk of all types of stroke (RR = 0.74, 95% CI 0.56-0.97), highlighting its broader cardiovascular benefits beyond heart failure outcomes.
• Improvements in quality of life and cardiac function, such as better Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, left atrial volume index (LAVI), and left ventricular ejection fraction (LVEF), were observed with sotagliflozin, further supporting its beneficial effects in heart failure patients.
• Sotagliflozin increased the risk of genital mycotic infections in patients with type 1 diabetes (T1D) and type 2 diabetes (T2D), with risk ratios of 3.49 and 2.83, respectively.
• Sotagliflozin was associated with a higher risk of diarrhea and volume depletion in both T1D and T2D populations.
• Sotagliflozin increased the risk of acidosis-related events, including diabetic ketoacidosis (DKA), particularly in patients with T1D.
• Sotagliflozin demonstrated cardiovascular benefits in type 2 diabetes mellitus (T2DM) patients with heart failure (HF) or cardiovascular risk factors, particularly reducing cardiovascular-related deaths and hospitalizations for heart failure. Additionally, sotagliflozin showed beneficial effects in patients with chronic kidney disease (CKD), with or without albuminuria.